Selective Killing of Cancer Cells Based on Loss of Heterozygosity and Normal Variation in the Human Genome: A New Paradigm for Anticancer Drug Therapy-Reference-Cited by-同舟云学术

Selective Killing of Cancer Cells Based on Loss of Heterozygosity and Normal Variation in the Human Genome: A New Paradigm for Anticancer Drug Therapy

Published:1999-08-01 Issue:2 Volume:56 Page:359-369
ISSN:0026-895X
Container-title:Molecular Pharmacology
language:en
Short-container-title:Mol Pharmacol

Author:

Basilion James P.,Schievella Andrea R.,Burns Erica,Rioux Patrice,Olson Jeffrey C.,Monia Brett P.,Lemonidis Kristina M.,Stanton Vincent P.,Housman David E.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference39 articles.

1. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.;Bennett;Mol Pharmacol,1992

2. Bennett CF Dean N Ecker DJ Monia BP (1996) Pharmacology of antisense therapeutic agents. in Antisense Therapeutics, ed Agrawal S (Humana Press, Totowa), pp 13–46.

3. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

4. Replication factor-A from Saccharomyces cerevisiae is encoded by three essential genes coordinately expressed at S phase.

5. Analysis of RNA by Northern and slot blot hybridization;Brown;Current Protocols in Molecular Biology,1987

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Membrane Anchorage‐Induced (MAGIC) Knockdown of Non‐synonymous Point Mutations**;ChemBioChem;2022-04-20

2. A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo;Science Translational Medicine;2022-03-02

3. Targeting loss of heterozygosity for cancer-specific immunotherapy;Proceedings of the National Academy of Sciences;2021-03-17

4. Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy;Pharmaceuticals;2021-01-13

5. Engineered T cells directed at tumors with defined allelic loss;Molecular Immunology;2020-12